Components of Placebo Effect: Randomised Controlled Trial in Patients with Irritable Bowel Syndrome

被引:0
|
作者
Hummelsberger, J. [1 ]
机构
[1] Chinese Med SMS Societas Med Sinensis, Int Soc, Hackenstr 7 C, D-80331 Munich, Germany
来源
DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR | 2010年 / 53卷 / 02期
关键词
D O I
10.1016/j.dza.2010.04.011
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: To investigate whether placebo effects can experimentally be separated into the response to three components - assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient- practitioner relationship - and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. Design: A six week single blind three arm randomised controlled trial. Setting Academic medical centre. Participants 262 adults (76 % women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of >= 150 on the symptom severity scale. Interventions: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient- practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. Main outcome measures Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. Results: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P < 0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28 % on waiting list, 44 % in limited group, and 62 % in augmented group (P < 0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P < 0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P < 0.001). All pairwise comparisons between augmented and limited patient- practitioner relationship were significant: global improvement scale (P < 0.001), adequate relief of symptoms (P < 0.001), symptom severity score (P = 0.007), quality of life (P = 0.01). Results were similar at six week follow-up. Conclusion Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient- practitioner relationship is the most robust component.
引用
收藏
页码:41 / 42
页数:3
相关论文
共 50 条
  • [21] Acupuncture for irritable bowel syndrome: A protocol for a pragmatic randomised controlled trial
    MacPherson, Hugh
    Bland, Martin
    Bloor, Karen
    Cox, Helen
    Geddes, David
    Kang'ombe, Arthur
    Reynolds, Julie
    Stamuli, Eugena
    Stuardi, Tracey
    Tilbrook, Helen
    Torgerson, David
    Whorwell, Peter
    BMC GASTROENTEROLOGY, 2010, 10
  • [22] Hypnotherapy for irritable bowel syndrome (IBS) - A blinded randomised controlled trial
    Forbes, A
    Macauley, S
    Chiotakakou-Faliakou, E
    GUT, 1999, 44 : A14 - A14
  • [23] Acupuncture for irritable bowel syndrome: A protocol for a pragmatic randomised controlled trial
    Hugh MacPherson
    Martin Bland
    Karen Bloor
    Helen Cox
    David Geddes
    Arthur Kang'ombe
    Julie Reynolds
    Eugena Stamuli
    Tracey Stuardi
    Helen Tilbrook
    David Torgerson
    Peter Whorwell
    BMC Gastroenterology, 10
  • [24] Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome Comment
    Shah, Eric D.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (06): : 416 - 417
  • [25] Randomised controlled trial of brief intervention with biofeedback and hypnotherapy in patients with refractory irritable bowel syndrome
    Dobbin, A.
    Dobbin, J.
    Ross, S. C.
    Graham, C.
    Ford, M. J.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2013, 43 (01): : 15 - 23
  • [26] Effect of autogenic training in patients with irritable bowel syndrome: A randomized controlled trial
    Shinozaki, Masae
    Kanazawa, Motoyori
    Kano, Michiko
    Endo, Yuka
    Hongo, Michio
    Fukudo, Shin
    GASTROENTEROLOGY, 2006, 130 (04) : A502 - A502
  • [27] Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
    Hamatani, Tatsuto
    Fukudo, Shin
    Nakada, Yosuke
    Inada, Hiroshi
    Kazumori, Kiyoyasu
    Miwa, Hiroto
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (03) : 430 - 441
  • [28] Effect of Ramosetron in Female Patients With Irritable Bowel Syndrome With Diarrhea: A Randomized, Placebo-Controlled Phase III Trial
    Fukudo, Shin
    Kinoshita, Yoshikazu
    Okumura, Toshikatsu
    Ida, Motoko
    Akiho, Hiraku
    Nakashima, Yoshihiro
    Nishida, Akito
    Haruma, Ken
    GASTROENTEROLOGY, 2015, 148 (04) : S70 - S70
  • [29] Interim results of a randomised controlled trial of homeopathic treatment for irritable bowel syndrome
    Peckham, Emily J.
    Relton, Clare
    Raw, Jackie
    Walters, Clare
    Thomas, Kate
    Smith, Christine
    Kapur, Kapil
    Said, Elmuhtady
    HOMEOPATHY, 2014, 103 (03) : 172 - 177
  • [30] Synbiotics in irritable bowel syndrome: A double blind prospective randomised controlled trial
    Barker, P
    McNaught, CE
    Anderson, ADG
    Mitchell, CJ
    MacFie, J
    GUT, 2003, 52 : A11 - A11